Join Hands, Create the Future Together | Shenyang DASAN and Oxiran Pharmaceutical Sign Strategic Cooperation Agreement
Posting Date：2024-11-20Views：
On November 18, 2024, Shenyang DASAN Pharmaceutical Technology Co., Ltd. and Liaoning Oxiran Pharmaceutical Co., Ltd. officially signed a strategic cooperation agreement, marking a significant step in their in-depth collaboration within the pharmaceutical industry.
Attendees at the signing ceremony included Chen Yangying, Chairman of Oxiran Pharmaceutical; Lyu Shisen, General Manager; Guo Yang, Deputy General Manager; Zhao Chunyu, R&D Manager; Li Shi, Sales Director; Zhang Bing, Quality Manager; and Ai Long, Production Manager. Representing Shenyang DASAN were Yan Dong, General Manager; Chen Xu, Deputy General Manager of Production; Lei Jiang, R&D Director; Wang Xinyu, Deputy General Manager of Administration; and Sang Rou, Quality Manager.
The signing of this strategic cooperation agreement marks not only a new starting point for the collaboration between Shenyang DASAN and Liaoning Oxiran in the pharmaceutical industry but also a significant initiative for both parties to jointly address market challenges and promote industry development. We look forward to achieving optimal resource allocation through close cooperation, driving the sustainable development of the pharmaceutical industry, and providing patients with safer and more effective drug solutions.
Oxiran Pharmaceutical is a national high-tech enterprise integrating R&D, production, and sales. Its main products fall into three major series: polyethylene glycol series, polyoxyl stearate (40) ester, and polysorbate 80, widely used in various dosage forms such as dropping pills, suppositories, electrolyte powders, soft capsules, and tablets.
Shenyang DASAN Pharmaceutical Technology Co., Ltd. is a Sino-Korean joint venture pharmaceutical R&D enterprise. Its primary research focus is on the development and industrialization of complex oral formulation processes. The company has established multiple platforms for the development and industrial technology of complex formulations and has been certified as a National High-Tech Enterprise twice. It provides full-lifecycle pharmaceutical services, from project initiation to R&D, manufacturing, registration, and final market launch, operating as a "Pharmaceutical R&D + MAH Manufacturing Company (B-Certificate)."
Posting Date：2024-11-20
Views： 
Previous：
Back to List